Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing and commercializing seralutinib (GB002), an investigational inhaled small molecule inhibitor of PDGFR, CSF1R, and c-KIT, for the treatment of pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease (PH-ILD). The company completed a Phase 3 PROSERA trial in 390 PAH patients and is pursuing FDA regulatory feedback for a potential NDA submission, while also advancing RT234 under an option agreement with Respira Therapeutics.
expected 2026-12-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-17 | 2025-12-31 | 0001728117-26-000017 | EDGAR | 94K words |
| 2025-03-13 | 2024-12-31 | 0001728117-25-000021 | EDGAR | 88K words |
| 2024-03-05 | 2023-12-31 | 0001728117-24-000019 | EDGAR | 83K words |
| 2023-03-17 | 2022-12-31 | 0001728117-23-000010 | EDGAR | — |
| 2022-03-03 | 2021-12-31 | 0001728117-22-000019 | EDGAR | — |
| 2021-02-26 | 2020-12-31 | 0001728117-21-000019 | EDGAR | — |
| 2020-03-24 | 2019-12-31 | 0001564590-20-012323 | EDGAR | — |
| 2019-03-22 | 2018-12-31 | 0001564590-19-009031 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-13 | 2026-06-30 | 0001728117-26-000072 | EDGAR | 32K words |
| 2025-11-05 | 2025-09-30 | 0001728117-25-000081 | EDGAR | 22K words |
| 2025-08-05 | 2025-06-30 | 0001728117-25-000068 | EDGAR | 22K words |
| 2025-05-15 | 2025-03-31 | 0001728117-25-000036 | EDGAR | 19K words |
| 2024-11-07 | 2024-09-30 | 0001728117-24-000092 | EDGAR | 23K words |
| 2024-08-12 | 2024-06-30 | 0001728117-24-000085 | EDGAR | 22K words |
| 2024-05-07 | 2024-03-31 | 0001728117-24-000056 | EDGAR | 18K words |
| 2023-11-09 | 2023-09-30 | 0001728117-23-000134 | EDGAR | 22K words |
| 2023-08-08 | 2023-06-30 | 0001728117-23-000108 | EDGAR | 20K words |
| 2023-05-09 | 2023-03-31 | 0001728117-23-000049 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001728117-22-000100 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001728117-22-000085 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-23 | 0001728117-26-000104 | EDGAR | 1K words |
| 2026-09-16 | 0001728117-26-000101 | EDGAR | 1K words |
| 2026-09-11 | 0001728117-26-000094 | EDGAR | 1K words |
| 2026-09-09 | 0001728117-26-000091 | EDGAR | 1K words |
| 2026-09-03 | 0001728117-26-000085 | EDGAR | 16K words |
| 2026-08-26 | 0001728117-26-000079 | EDGAR | 8K words |
| 2026-08-21 | 0001728117-26-000077 | EDGAR | 2K words |
| 2026-08-13 | 0001728117-26-000073 | EDGAR | 2K words |
| 2026-07-27 | 0001728117-26-000064 | EDGAR | 10K words |
| 2026-07-15 | 0001728117-26-000061 | EDGAR | 12K words |
124 total filings indexed. 94 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001728117 |
| Ticker | GOSS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.gossamerbio.com |
| Listed | 2019-02-08 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/GOSS (~200 tokens, structured JSON with cryptographic provenance)